/l platelets. 6, 7 The sole expert reading of histopathology (not even taking the platelet counts into account) is diagnostic for essential thrombocythemia. 5 Therefore, the fourth criterion of the new proposal, that is, exclusion of reactive thrombocytosis in cases without demonstration of JAK2 V617F or other clonal marker may be excessive. (The same holds true for an analogous formulation in the criteria for PMF).
The first major PMF criterion, 1 histopathology, verbally admits the diagnosis of 'prefibrotic cellular phase' of the disease. However, this stage is practically precluded by the demand to fulfill at least two minor criteria: it has to be understood that three of the four minor criteria given (leukoerythroblastosis, anemia and palpable splenomegaly) 1 are features of more advanced PMF and only extremely rarely occur at diagnosis of the prefibrotic stage of PMF. 8 Renaming MPD as 'neoplasms' does not seem to be a well-chosen word either. Patients with a relatively benign myeloproliferation, such as essential thrombocythemia, will uselessly have this somewhat frightening word in their medical records.
The Czech MPD Working Group cannot advocate the currently published WHO 2008 1 criteria for routine usage for reasons given above. Morever, these criteria lack the nosologic clarity of the former criteria, 8 which were largely based on histopathology (originally worked out by the Hannover and later Cologne histopathological schools in Germany) and recognized the respective disease entity from its onset until late complications, without any need to change the name of the disease. Partially human leukocyte antigen (HLA)-mismatched allogeneic hematopoietic stem cell transplantation (allo-HSCT) from haploidentical family, unrelated and cord blood donors, has during recent years become an important and feasible therapeutic option for the almost 50% of patients affected by high-risk hematologic malignancies lacking an HLAidentical sibling donor. 1 In these patients, the curative efficacy of allo-HSCT is critically dependent on timely detection of recurrent disease, necessary for undertaking pre-emptive therapeutic measurements, such as down-tapering of immune suppressive drugs or administration of donor lymphocyte infusions (DLI) to promote graft versus leukemia (GvL) activity. 2 Tumor-specific molecular markers such as oncogene rearrangements for detection of minimal residual disease (MRD) are only available for approximately 30% of patients. 3 For the remaining 70%, the status of host chimerism (HC) after allo-HSCT can be a useful surrogate marker for MRD. 4 Currently, the standard reference method for HC analysis is the genomic detection of patient and donor-specific short tandem repeats (STR), a reliable method suitable for quantitative HC analysis with a reported sensitivity of around 5%, which limits its efficacy in the determination of low levels of HC as surrogate marker for MRD. 5 To test whether detection of patient-specific HLA alleles by standard genomic typing could increase the sensitivity of HC analysis after allo-HSCT from alternative donors, we first validated hybridization-based PCR sequence-specific oligonucleotide probing (SSO) using the Dynal RELI SSO kit for HLA-A, B, C, DRB, DQB1, and sequence-specific priming (SSP) using the Olerup SSP kit for HLA-DPB1, on a reference standard curve (details on Materials and methods can be viewed in the Supplementary Material). SSO and SSP were shown to have a sensitivity of 1 and 5%, respectively (Supplementary Figure 1 in Supplementary Material and data not shown). Next, we comparatively evaluated HC analysis by STR and HLA typing in bone marrow (BM) follow-up samples of allo-HSCT from alternative, at least one HLA allele-mismatched donors, with a total of 183 and 100 parallel tests for STR and SSO or STR and SSP, respectively. The overall concordance was 81.4% for STR and SSO, and 80% for STR and SSP (Table 1 ). In 3.3 and 4% of the analyses, respectively, negative results of SSO and SSP contrasted a positive STR. All of these cases were subsequently shown to be false positive STR results, as none of them was followed by a clinical event explaining a positive HC, such as relapse, graft rejection or persistent mixed chimerism (PMC). Conversely, 15.3 and 16% of positive SSO and SSP results, respectively, contrasted a negative STR (Table 1) . Overall, 42.9% of these SSO and 12.5% of these SSP results were true positive, as evidenced by subsequent onset of a clinical event explaining a positive HC, such as relapse, graft rejection or PMC (data not shown).
To determine the value of HLA typing for the detection of disease recurrence, we studied 28 informative patients who underwent a total of 29 allo-HSCT from partially HLA-mismatched alternative donors for high-risk hematologic malignancies (Table 2) . To avoid confounding effects by residual host cells in the early engraftment phase, HC results were considered only from day 60 after transplantation, a time point at which all patients presented 42000 white blood cells per microliter in the peripheral blood and BM, allowing us to obtain sufficient amounts of genomic DNA for reliable HLA typing and STR analysis in all cases. The number of informative probes or mixes for HC detection in these transplants ranged between 1 and 22 for SSO and between 1 and 14 for SSP (data not shown). In 11 transplants, clinical relapse, as defined by 45% of leukemic blasts in morphological analysis of BM aspirate, was observed after initial conversion to full-donor chimerism. In 2 out of these 11 cases, no positive HC was observed in two analyses performed for each patient before the onset of relapse (Figure 1a) . Of the remaining nine cases, six were predicted by STR and eight by SSO, whereas SSP predicted three out of four relapses occurring in transplants monitored by this method. Relapse prediction by SSO and SSP was independent of the number of informative probes or primer mixes present (data not shown). Of the six relapses predicted by STR, only one was not predicted by SSO, whereas of the eight relapses predicted by SSO, three were not predicted by STR. Interestingly, in two out of five relapses predicted by both STR and SSO, a positive signal was detected by SSO at least 1 month before STR (Figure 1a ). Of note, SSO documented a positive HC also before cytogenetics for the t(6;15) translocation (Figure 1b) , and before Y-chromosome- On the basis of these observations, the sensitivity of a single positive (SP) result in STR, SSO and SSP for prediction of disease recurrence after HLA-mismatched allo-HSCT was 55, 82 and 75%, respectively (Table 3) . However, a positive HC was observed in clinically eventless transplants with a higher frequency by SSO (7 out of 14) and SSP (5 out of 9) as compared to STR (5 out of 19), resulting in a lower specificity of 50 and 44% for SSO and SSP, respectively, as opposed to 74% for STR (Table 3) . This suggests that an isolated SP HC in SSO and SSP must be interpreted with caution.
We therefore asked whether the specificity of HLA typing for disease recurrence could be increased by considering a SP HC together with the presence or absence of at least one concomitant suspect (CS). CS was defined as the presence of 3-5% blasts in morphological analysis of BM aspirate, cytogenetic alterations, positive FISH analysis for male-specific signals (in the case of female donors and male recipients), or a disease cluster defined by multicolor flow-cytometric analysis. When the same transplants were analyzed for the presence of SP HC in concomitance with CS (SP þ CS), specificity of HLA typing for detection of relapse increased to 79 and 75% for SSO and SSP, respectively, with a slight decrease in sensitivity for SSO but not for SSP (Table 3) . Interestingly, in seven out of eight relapses predicted by SSO, at least one SP HC was observed in concomitance with CS (Figure 1a) , further underscoring the predictive value of this type of analysis. In three of the five relapses predicted by SSO that were monitored more than once for HC before clinical onset of relapse, two consecutive positive (TCP) HC were observed, but in all three cases, relapse was also predicted by SP þ CS (Figure 1a) . Overall, the sensitivity of TCP, which could be monitored only in 23 transplants due to insufficient follow-up before relapse in the remaining transplants, was significantly lower as compared to SP or SP þ CS for both STR, SSO and SSP, with SSP being unable to predict any of the three relapses occurring in nine informative transplants ( Table 3 ), suggesting that TCP should not be used as isolated parameter for prediction of disease relapse.
Taken together, even though the reported results were obtained on a limited number of transplants, our data suggest that HC by HLA typing is an efficient tool for early detection of MRD, especially when present in concomitance with a CS as defined above. This observation will be useful for the constantly rising number of patients undergoing allo-HSCT from alternative donors for neoplastic hematopoietic disorders at high risk of relapse, and it can potentially be applied also to HSCT from HLA-identical sibling donors presenting minor histocompatibility antigen mismatches. 
